Novo Nordisk CEO addresses concerns surrounding Catalent's Ozempic and Wegovy, discussing safety issues with off-label use of diabetes drugs. Investors seeking insights on Novo Nordisk's performance and valuation should consider this essential information for a comprehensive stock analysis. Stay informed with our expert overview.